Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma

BACKGROUND: Although epidermal growth factor receptor (EGFR) and its truncated, autoactive mutant EGFR variant (v)III are bona fide drivers of tumorigenesis in some gliomas, therapeutic antibodies developed to neutralize this axis have not improved patient survival in a limited number of trials. Pre...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Greenall, Sameer A, McKenzie, Mathew, Seminova, Ekatarina, Dolezal, Olan, Pearce, Lesley, Bentley, John, Kuchibhotla, Mani, Chen, Shengnan C, McDonald, Kerrie L, Kornblum, Harley I, Endersby, Raelene, Adams, Timothy E, Johns, Terrance G
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Basic and Translational Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6682217/
https://ncbi.nlm.nih.gov/pubmed/31002307
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz073
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados